IP Library Granted Patent US 10,000,492
Granted Patent B2
US 10,000,492 · App. 15/613,620 · Granted Jun 19, 2018

Process for producing diazabicyclooctane derivative

Inventors: Takao Abe (Kanagawa, JP); Takeshi Furuuchi (Kanagawa, JP); Yoshiaki Sakamaki (Kanagawa, JP); Nakako Mitsuhashi (Kanagawa, JP)
Assignee: MEIJI SEIKA PHARMA CO., LTD.
C07D471/08C07D211/60C07D401/12Y02P20/55
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,000,492
App. No.
15/613,620
Granted
Jun 19, 2018
Kind
B2
Abstract

A process for producing a compound represented by a Formula (III), including reacting a compound of the following formula with a compound selected from the group consisting of 1-hydroxypyrrolidine-2,5-dione, 2-hydroxy-3a,4,7,7a-tetrahydro-1H-isoindol-1,3(2H)-dione, 2-hydroxyhexahydro-1H-isoindol-1,3(2H)-dione and 4-hydroxy-4-azatricyclo[5.2.1.0 2,6 ]dec-8-ene-3,5-dione, carrying out a carbonylation to obtain a compound of the following formula removing the NH protecting group P and treating the resultant compound with a base to produce a compound represented by the following formula wherein OBn is benzyloxy and R 2 is hydrogen, ClCO— or Cl 3 COCO—.

Claims (17)

1. A process for producing a compound represented by a Formula (III), comprising: reacting a compound represented by the following Formula (I):

with a compound selected from the group consisting of 1-hydroxypyrrolidine-2,5-dione, 2-hydroxy-3a,4,7,7a-tetrahydro-1H-isoindol-1,3(2H)-dione, 2-hydroxyhexahydro-1H-isoindol-1,3(2H)-dione and 4-hydroxy-4-azatricyclo[5.2.1.0 2,6 ]dec-8-ene-3,5-dione, allowing a carbonylating agent selected from the group consisting of phosgene, diphosgene and triphosgene to act on the resultant compound to obtain a compound represented by the following Formula (II):

removing the protecting group P and treating the resultant compound with a base to produce a compound represented by the following Formula (III):

wherein in said Formulas (I), (II) and (III), OBn is benzyloxy; P is an NH protecting group capable of being removed with an acid; R 1 is 2,5-dioxopyrrolidin-1-yl, 1,3-dioxo-3a,4,7,7a-tetrahydro-1H-isoindol-2(3H)-yl, 1,3-dioxohexahydro-1H-isoindol-2(3H)-yl or 3,5-dioxo-4-azatricyclo[5.2.1.0 2,6 ]dec-8-en-4-yl and R 2 is hydrogen, ClCO— or Cl 3 COCO—.

2. The process according to claim 1 , wherein P is tert-butoxycarbonyl.

3. The process according to claim 1 , wherein R 1 is 2,5-dioxopyrrolidin-1-yl.

4. The process according to claim 1 , wherein R 1 is 1,3-dioxo-3a,4,7,7a-tetrahydro-1H-isoindol-2(3H)-yl.

5. The process according to claim 1 , wherein R 1 is 1,3-dioxohexahydro-1H-isoindol-2(3H)-yl.

6. The process according to claim 1 , wherein R 1 is 3,5-dioxo-4-azatricyclo[5.2.1.0 2,6 ] dec-8-en-4-yl.

7. A process for producing a compound represented by a Formula (III), comprising: allowing a carbonylating agent selected from the group consisting of phosgene, diphosgene and triphosgene to act on a compound represented by the following Formula (II):

removing the protecting group P and treating the resultant compound with a base to produce the compound represented by the following Formula (III):

wherein in said Formulas (II) and (III), OBn is benzyloxy; P is an NH protecting group capable of being removed with an acid; R 1 is 2,5-dioxopyrrolidin-1-yl, 1,3-dioxo-3a,4,7,7a-tetrahydro-1H-isoindol-2(3H)-yl, 1,3-dioxohexahydro-1H-isoindol-2(3H)-yl or 3,5-dioxo-4-azatricyclo[5.2.1.0 2,6 ]dec-8-en-4-yl and R 2 is hydrogen.

8. The process according to claim 7 , wherein P is tert-butoxycarbonyl.

9. The process according to claim 7 , wherein R 1 is 2,5-dioxopyrrolidin-1-yl.

10. The process according to claim 7 , wherein R 1 is 1,3-dioxo-3a,4,7,7a-tetrahydro-1H-isoindol-2(3H)-yl.

11. The process according to claim 7 , wherein R 1 is 1,3-dioxohexahydro-1H-isoindol-2(3H)-yl.

12. The process according to claim 7 , wherein R 1 is 3,5-dioxo-4-azatricyclo[5.2.1.0 2,6 ] dec-8-en-4-yl.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2017
From: ABE, TAKAO; FURUUCHI, TAKESHI; SAKAMAKI, YOSHIAKI; MITSUHASHI, NAKAKO
To: MEIJI SEIKA PHARMA CO., LTD.
Reel/Frame 042596/0923 →
Priority Claims (1)
JP 2013-197110 · Sep 24, 2013 · national
Continuity (2)
Division 15023976
Related Publication 20170283415A1 · Oct 5, 2017
Cited By (3)
US 12,195,755 US 12,221,443 US 12,509,559